Barclays’s Gain Therapeutics GANX Stock Holding History

Barclays’s Portfolio GANX Stock Details GANX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.75K	Buy	+1,352	New	+$2.49K	﹤0.01%	4838

Other funds holding GANX

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

PCM

Potomac Capital Management New York $147M AUM

GCP

GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

DCM

DME Capital Management New York $3.91B AUM 36.1% 1-Year Est. Return

Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Barclays's GANX Position: Q2 2026 in Review

Barclays opened a new position in Gain Therapeutics (GANX) in Q2 2026: 1,352 shares worth $2.75K. The stake represents ﹤0.01% of the portfolio and ranks #4838 among its holdings.

50 funds tracked by Wall St. Rank hold GANX as of Q2 2026.

Barclays held 1,352 shares of Gain Therapeutics worth $2.75K as of Q2 2026.
Gain Therapeutics was a new Barclays position in Q2 2026.
Gain Therapeutics made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #4838 holding.
50 funds tracked by Wall St. Rank held Gain Therapeutics as of Q2 2026.

Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.